Archived Monthly Oncology Tumor Boards: Diagnosis and Management of Marginal Zone Lymphomas

Marginal zone lymphomas (MZLs) represent a clinical challenge due to their heterogeneity, and the relative rarity of individual subtypes has largely precluded the use of standard treatment approach across all subtypes. In recent years, improved understanding of the complex pathobiology of MZLs has resulted in the development of  novel treatment strategies. Adequate hematopathology review of biopsy and immunophenotyping are needed to establish the diagnosis of a specific subtype of MZL. In addition, endoscopic assessment of the GI tract and evaluation of the tumor specimen for the presence of underlying infection should be performed for patients with gastric and non-gastric MALT lymphomas. Clinicians need to understand the importance of treating the underlying infectious condition in patients with MZLs. Educating clinicians about the biology of MZLs, novel therapeutic approaches, and special considerations will help them to develop an individualized treatment plan to optimize clinical outcomes. 

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the etiology and genetic features of unique subtypes of marginal zone lymphomas (MZL).
  • Review current treatment approaches for patients with MZL based on the individual subtypes.
  • Summarize the role of targeted therapies for the treatment of patients with MZL, and opportunities for collaborative management with pharmacists.
Additional information

This activity is supported by educational grants from: 

  • AstraZeneca
  • Blueprint Medicines
  • Epizyme Inc.
  • GlaxoSmithKline
  • Lilly
  • Novartis
  • Puma Biotechnology
  • Sanofi Genzyme

This activity is supported by independent medical education grants from:

  • Bristol Myers Squibb
  • Illumina, Inc
  • Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc. 

This activity is supported by an independent educational grant from Astellas.

This educational activity is supported by a medical education grant from Exelixis, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
Course expires: 

Stephen D. Smith, MD 
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Ivan J. Huang, PharmD, BCOP
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance


NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Ivan J. Huang, PharmD, BCOP

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Stephen D. Smith, MD
Acerta Pharma: Grant/Research Support 
ADC Therapeutics: Scientific Advisor 
AstraZeneca Pharmaceuticals LP: Consulting Fee; Grant/Research Support 
Ayala: Consulting Fee; Grant/Research Support 
Bayer HealthCare: Grant/Research Support 
BeiGene: Grant/Research Support; Scientific Advisor 
Bristol-Myers Squibb Company: Consulting Fee; Grant/Research Support 
Denovo Biopharma: Consulting Fee; Grant/Research Support
Genentech, Inc.: Consulting Fee; Grant/Research Support 
Ignyta: Grant/Research Support 
Incyte Corporation: Grant/Research Support
Karyopharm Therapeutics: Consulting Fee 
Kite Pharma: Consulting Fee 
Merck & Co., Inc. Grant/Research Support 
Millennium Pharmaceuticals, Inc.: Consulting Fee 
Pharmacyclics: Grant/Research Support 
Portola Pharmaceuticals, Inc.: Grant/Research Support 

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.


In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-026-H01-P

Physician Assistants 
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until February 23, 2023. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1.0 CE contact hour. Activity Code: I00049424; Approval #: 220000267

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing